Atea Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Atea Pharmaceuticals's estimated annual revenue is currently $207.8M per year.
- Atea Pharmaceuticals's estimated revenue per employee is $2,474,048
- Atea Pharmaceuticals's total funding is $283.4M.
- Atea Pharmaceuticals's current valuation is $606.6M. (January 2022)
Employee Data
- Atea Pharmaceuticals has 84 Employees.
- Atea Pharmaceuticals grew their employee count by 9% last year.
Atea Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Founder, Chairman & CEO | Reveal Email/Phone |
2 | CFO & EVP, Legal | Reveal Email/Phone |
3 | EVP, Head Regulatory Affairs and Quality Assurance | Reveal Email/Phone |
4 | VP, Virology | Reveal Email/Phone |
5 | EVP, Preclinical Science | Reveal Email/Phone |
6 | EVP, Chemistry | Reveal Email/Phone |
7 | SVP, Investor Relations & Corporate Communications | Reveal Email/Phone |
8 | VP, Clinical Operations and Project Management | Reveal Email/Phone |
9 | SVP, Investor Relations and Corporate Communications | Reveal Email/Phone |
10 | VP, Biostatistics | Reveal Email/Phone |
Atea Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.7M | 82 | -45% | $107.3M | N/A |
#2 | $0.2M | 1 | -50% | N/A | N/A |
#3 | $6.2M | 40 | 21% | N/A | N/A |
#4 | $42.2M | 218 | 4% | $165M | N/A |
#5 | $14.6M | 94 | -37% | $312.8M | N/A |
#6 | $0.3M | 2 | -67% | N/A | N/A |
#7 | $235M | 366 | -5% | $340.9M | N/A |
#8 | $56M | 289 | -7% | $7.6M | N/A |
#9 | $4.7M | 61 | 36% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is Atea Pharmaceuticals?
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company working to address unmet medical needs through novel antiviral treatment.
keywords:N/A
$283.4M
Total Funding
84
Number of Employees
$207.8M
Revenue (est)
9%
Employee Growth %
$606.6M
Valuation
N/A
Accelerator
Atea Pharmaceuticals News
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Short Interest Update Defenseworld.net
Atea Pharmaceuticals Reports Nonclinical Bemnifosbuvir (AT-527 ... Kenosha News
Atea Pharmaceuticals Reports Nonclinical Bemnifosbuvir (AT-527 ... GlobeNewswire
Atea Announces Update on Collaboration with Roche for AT-527 TOKYO, November 17, 2021 --Chugai Pharmaceutical Co., Ltd.(TOKYO: 4519) announced that Atea issued a press release on its collaboration with Roche for the investigational oral COVID-19 treatment AT- 527. Please refer to the link belo ...
Atea Announces Update and Topline Results of MOONSONG Study Evaluating AT-527 for COVID-19 in the Outpatient Setting TOKYO, October 20, 2021 --Chugai Pharmaceutical Co., Ltd.(TOKYO: 4519) announced that Atea issued a press release on October 19 regarding update and topline results of MOONSONG ...
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $20.4M | 84 | -3% | N/A |
#2 | $15M | 84 | -10% | N/A |
#3 | $8.6M | 84 | N/A | N/A |
#4 | $19.1M | 84 | 8% | N/A |
#5 | $13.9M | 84 | 4% | N/A |